Anavex Life Sciences Corp (AVXL)

[falconer66a]

Targeting the root cause. It's not beta-amyloid.

The belief that Alzheimer's is caused by the aggregation of beta-amyloid plaques and neurofibrillary tangles is starting to get muddied and the "consensus" scientific opinion is no longer.

Actually, Alzheimer's symptoms are very clearly caused by these two protein waste accumulations. No one is really questioning that.

The treatment problem is that, until Anavex, researchers have focused on how to safely and effectively remove these proteins (a failure in every case). The approach is simplistic: beta-amyloid and tau tangle proteins disturb neuron function and cause Alzheimer's symptoms, so, just get rid of them and the problem is solved.

But, as numerous expensive trials have shown, these deposits are utterly recalcitrant, unable to be removed without serious, debilitating side effects. Hence, unknowledgeable scientific and financial advisors castigate Anavex, thinking its approach is like all the others that have failed.

Anavex will win, however. Instead of attacking the end-process problem, the existing protein waste deposits, Anavex 2-73 restores normal cell function ("homeostasis"), allowing properly-formed and fully-functional waste-clearing enzymes (folded properly in the rough endoplasmic reticulum, restored to function by the drug) to properly clear the wastes, as in the non-Alzheimer's state.

In short, Anavex 2-73 solves the problem at it's root, not at the end-stage. The root cause of the Alzheimer's problem is the neurons no longer synthesize normal, properly-functioning enzymes that otherwise wok normally, creating normal cell biochemistry (the homeostasis).

All of this is a bit beyond most financial advisors, it appears. Just when they will have to confront the profound reality of the Anavex Central Nervous System disorder revolution will be interesting to watch.

The only people of real significance in the matter are the scientific minds at Anavex, and FDA officials who will, soon enough, realize a) the remarkable biochemistry and safety of the Anavex molecules, and b) the profound fit of Anavex technologies with the Trump FDA quick cures imperatives.

Anavex successfully fixes the root cause of Alzheimer's; doesn't mess with insolvable down-stream outcomes of chemical or immunological waste removals.